Celltrion Gestione

Criteri Gestione verificati 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Hyong-Gi Kim

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	11.7yrs
Proprietà del CEO	0.1%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	3.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Hyong-Gi Kim (60 yo)

11.7yrs

Mandato

Mr. Hyong-Gi Kim serves as Co-Chief Executive Officer at Celltrion, Inc. Mr. Kim served as Vice President of Celltrion Pharm Inc. He served as Head of Strategy and Planning Team, Daewoo Motor Company. He s...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Hyong-Gi Kim	Co-CEO & Internal Director	11.7yrs	Nessun dato	0.10% ₩ 42.2b
Woo-Sung Kee	Co-CEO & Internal Director	11.7yrs	Nessun dato	0.093% ₩ 37.9b
Jin-Seok Seo	Co-CEO & Inside Co-Chairman of the Board	4.7yrs	Nessun dato	0.0015% ₩ 605.1m
Jung-Jin Seo	Inside Co-Chairman of the Board	13.7yrs	Nessun dato	4.38% ₩ 1.8t
Soon-Woo Lee	Independent Director	3.7yrs	Nessun dato	Nessun dato
Joong Jae Lee	Independent Director	1.9yrs	Nessun dato	0.000010% ₩ 4.1m
Byung-oh Kwon	Director	no data	Nessun dato	0.00093% ₩ 377.7m
Keun-young Kim	Independent Director	3.7yrs	Nessun dato	Nessun dato
Young-hyeh Ko	Independent Director	3.7yrs	Nessun dato	Nessun dato
Jae-sik Lee	Independent Director	3.7yrs	Nessun dato	Nessun dato
Dae-hyun Yoo	Independent Director	3.7yrs	Nessun dato	Nessun dato
Jong moon Choi	Independent Director	1.9yrs	Nessun dato	Nessun dato

3.7yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di A068270 sono considerati esperti (durata media dell'incarico 3.7 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/11/28 01:52
Prezzo dell'azione a fine giornata	2025/11/28 00:00
Utili	2025/09/30
Utili annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Celltrion, Inc. è coperta da 37 analisti. 22 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Girish Bakhru	BofA Global Research
Dae Woong Yoo	Bookook Securities Co. Ltd
Hyeryeong Kim	CGS International

Celltrion Gestione

Criteri Gestione verificati 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Celltrion, Inc., Annual General Meeting, Mar 25, 2025

Celltrion, Inc., Annual General Meeting, Mar 26, 2024

Less than half of directors are independent

Less than half of directors are independent

Celltrion, Inc., Annual General Meeting, Mar 26, 2021

Recent updates

Celltrion, Inc. Receives Health Canada Approval for Eydenzelt®?, a Biosimilar Confirming Eylea®? (aflibercept 2Mg)

Celltrion Announces Publication of Post-Hoc Analysis of Liberty-Cd Study of Zymfentra®? (Infliximab-Dyyb)

Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Celltrion, Inc Announces European Commission Grants Approval of Remsima™? IV Liquid Formulation, World's First Liquid Formulation of IV Infliximab

Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™? 300Mg

Consensus EPS estimates increase by 23%

Celltrion (KRX:068270) Has A Pretty Healthy Balance Sheet

U.S. FDA Grants Interchangeability Designations to Celltrion's Denosumab Biosimilar, STOBOCLO (denosumab-bmwo) and OSENVELT (denosumab-bmwo)

FDA Approves Expanded Pediatric Indications for YUFLYMA®? (Adalimumab-Aaty) and Unbranded Adalimumab-AatY in the United States

Celltrion Receives U.S. FDA Approval for EYDENZELT®? (aflibercept-boav), Biosimilar Confirming EYLEA®? (aflibercept)

Celltrion, Inc. Presents Positive Real-World Data on Switching from Intravenous (Iv) to Subcutaneous (Sc) Injectioniximab At Ueg Week 2025 Meet the Expert Sessions

Celltrion, Inc. Launches AVTOZMA®? (Tocilizumab-anoh) Intravenous (IV) Formulation in the United States

Investors Interested In Celltrion, Inc.'s (KRX:068270) Earnings

Celltrion Announces Commercial Availability of Omlyclo Across Europe at EADV 2025

Health Canada Approves Celltrion's Stoboclo and Osenvelt®? (CT-P41), Denosumab Biosimilarars for the Treatment of All Indications Approved for the Reference Products, Prolia®? and Xgeva, Respective

Celltrion, Inc. Announces U.S. Food and Drug Administration Approves Expanded Indication for AVTOZMA (Tocilizumab-anoh) Intra (IV) Formulation in Cyprietary Release Syndrome (CRS)

Celltrion, Inc. (KOSE:A068270) proposed to acquire Biopharmaceutical Manufacturing Facility in the United States.

Celltrion, Inc. Announces U.S. FDA Approval of Additional Presentation of Steelara®? (Ustekinumab-Stba)

Celltrion's YUFLYMA® (Alalimumab-Aaty) Receives FDA Interchangeability Designation for All Its Approved Doseforms and Strengthens

Celltrion, Inc. to Report Q1, 2025 Results on May 09, 2025

Celltrion (KRX:068270) Takes On Some Risk With Its Use Of Debt

Celltrion, Inc. to Present Six Abstracts in Inflammative Disease Week at 2025 Digestive Disease Week®? (DDW)

U.S. FDA Grants Interchangeable Designation to Yuflyma (Alalimumab-Aaty)

Celltrion, Inc.'s (KRX:068270) Popularity With Investors Is Clear

Now 23% undervalued after recent price drop

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Celltrion Receives U.S. FDA Approval for STOBOCLO (denosumab-bmwo) and OSENVELT Biosimilarars Referencing PROLIA and XGEVA

Celltrion, Inc., Annual General Meeting, Mar 25, 2025

Celltrion Receives EC Approval for Avtozma® (CT-P47), A Biosimilar to Roactemra® (tocilizumab)

Celltrion, Inc. Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

Celltrion Unveils Strategic Vision for Advancing Its Innovative Drug Pipeline At the 43Rd Annual J.P. Morgan Healthcare Conference

Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

U.S. FDA Approves Celltrion's STEQEYMA® (Ustekinumab-Stba), a Biosimilar to Stelara® (ustekinumab)

Is Celltrion (KRX:068270) A Risky Investment?

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Celltrion Presents Additional Data from Phase III Randomized Controlled Trials to Further Support Biosimilarity for CT-41 (Biosimilar Candidate of Denosumab) and CT-P47 (Biosimilar Candidate of Tocilizumab) At American College of Rheumatology Convergence 2024

Consensus EPS estimates fall by 16%

Celltrion, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Celltrion Presents 2-Year Post-Hoc Analysis Findings for Subcutaneous Infliximab (CT-P13 SC), Highlighting Dose Escalation as an Option for Managing Loss of Response in Inflammatory Bowel Disease

Now 21% overvalued after recent price rise

Now 21% overvalued after recent price rise

European Commission Approves Celltrion's SteQeyma (CT-P43) A Biosimilar to Stelara (ustekinumab), for the Treatment of Multiple Chronic Inflammatory Diseases

Consensus EPS estimates fall by 21%

Celltrion Showcases Promising Results in Phase III study for CT-P47, A Biosimilar Candidate of Roactemra® (Tocilizumab) in Patients with Rheumatoid Arthritis (RA) at EULAR 2024

Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe

First quarter 2024 earnings released: EPS: ₩108 (vs ₩1,156 in 1Q 2023)

Now 21% overvalued after recent price rise

Consensus EPS estimates fall by 14%

Full year 2023 earnings released: EPS: ₩3,759 (vs ₩3,664 in FY 2022)

Consensus EPS estimates fall by 16%

Celltrion, Inc., Annual General Meeting, Mar 26, 2024

Celltrion Presents New Two-Year Data for Subcutaneous Injectiximab (CT-P13 SC) in Inflammative Bowel Disease (IBD)

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 22%

Upcoming dividend of ₩500 per share at 0.3% yield

Consensus EPS estimates fall by 19%

Celltrion, Inc. to Report Nine Months, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

First quarter 2023 earnings released: EPS: ₩1,156 (vs ₩756 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Celltrion Healthcare Announces Canadian Approval of Vegzelma® (Bevacizumab for Injection) for the Treatment of Five Types of Cancer

Upcoming dividend of ₩375 per share

Now 20% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: ₩1,328 (vs ₩907 in 2Q 2021)

Price target increased to ₩210,861

Consensus forecasts updated